BioSpace News Archive

Drug Development

J&J’s Tremfya Superior to Novartis’ Cosentyx in Head-to-Head Trial

Tremfya was being compared to Novartis’ Cosentyx (secukinumab) in a head-to-head study. In the trial, Tremfya showed that 84.5 percent of patients treated with the drug achieved at least 90 percent improvement in their baseline Psoriasis Area Severity Index (PASI) score at 48 weeks.

December 12, 2018
·
3 min read
·
Mark Terry
Business

Following Sanofi Cuts Last Week, Boehringer Ingelheim to Cut 327 Jobs in France

More pharma workers in France are receiving coal in their stockings this year after Germany-based Boehringer Ingelheim announced plans to cut about 300 jobs in that country as part of a reorganization of its operations in France.

December 12, 2018
·
2 min read
·
Alex Keown
Job Trends

Pfizer Transfers 100 Jobs to La Jolla Oncology Site as It Closes Facility in South San Francisco

Pfizer’s La Jolla cancer research center is set to grow by about 100 people. The pharma giant is transferring employees from a recently shuttered South San Francisco immunology site to bolster the work conducted near San Diego.

December 12, 2018
·
2 min read
·
Alex Keown